Valbiotis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.01.19	VALBIOTIS Appoints Josep INFESTA, International Expert in Consumer Healthcare, Head of Global Business Development (Businesswire)
07.01.19	VALBIOTIS is Taking Part in the 37th J.P. Morgan Healthcare Conference, from 7 to 10 January 2019 in San Francisco, California (Businesswire)
28.11.18	VALBIOTIS Recognized for its IPO at the 2018 INVESTOR AWARDS (Businesswire)
12.11.18	VALBIOTIS Announces Expansion of Application for VALEDIA to Include NASH Prevention (Businesswire)
06.11.18	VALBIOTIS Confirms the Publication of the Results from International Phase IIA Clinical Study Evaluating VALEDIA® for the Risk Reduction of Type 2 Diabetes, by Mid-2019 (Businesswire)
17.10.18	VALBIOTIS confirms its interest in the study of the intestinal microbiota, a promising field in the prevention of metabolic diseases (Businesswire)
08.10.18	VALBIOTIS Confirms Its International Expansion with the Appointment of Murielle CAZAUBIEL, Founder and Former Executive Director of Biofortis Mérieux Nutrisciences Europe (Businesswire)
03.10.18	VALBIOTIS - VALEDIA®: Key Data Supporting the Submission of a Health Claim, Selected and Presented at the EASD 54th Congress in Berlin (Businesswire)
10.07.18	VALBIOTIS Announces Positive Results from First Phase I/II Clinical Study of VAL-070 in Hypercholesterolemia (Businesswire)
07.06.18	VALBIOTIS Confirms Its Deployment in the United-States, to Prepare the Future Commercialization of VALEDIATM (Businesswire)
15.05.18	VALBIOTIS Initiates the Clinical Development of VALEDIATM in the United-States with the REVERSE-IT Clinical Study (Businesswire)
27.02.18	VALBIOTIS Completes Phase I/II Clinical Study Recruitment For VAL-070, a Product to Reduce a Cardiovascular Risk Factor (Businesswire)
23.02.18	VALBIOTIS: Financial Communication Calendar for 2018 (Businesswire)
22.01.18	VALBIOTIS Announces a Significant Effect of VALEDIA® on Intestinal Microbiota (Businesswire)
08.01.18	VALBIOTIS Invited to Participate in Annual J.P. Morgan Healthcare Conference (Businesswire)
06.12.17	VALBIOTIS Announces Positive Preclinical Results for TOTUM-63, the Active Ingredient in VAL-63-NAFLD, for Non-Alcoholic Fatty Liver (NAFL), a Risk Factor for NASH (Businesswire)
04.12.17	Metformin + TOTUM-63 Combination: VALBIOTIS Announces First Preclinical Data for Possible Use in Diabetes Real Life Practice (Businesswire)
08.11.17	VALBIOTIS: VALEDIA®: Launch of "Pivotal” REVERSE-IT Clinical Trial to Obtain a Health Claim (Businesswire)
16.10.17	VALBIOTIS: LIPIDRIVE®: Efficacy Confirmed in Three Models, Finalization of Recruitment for Phase I/II in Humans (Businesswire)
29.09.17	VALBIOTIS: First Half of 2017 (Businesswire)
20.09.17	International Pharmaceutical and Nutrition Expert Dr. Jean Zetlaoui Joins VALBIOTIS’ Supervisory Board (Businesswire)
14.09.17	VALBIOTIS: Pascal SIRVENT Appointed Director of Discovery and Preclinical Research (Businesswire)
06.09.17	VALBIOTIS Opens a New Clinical Investigation Center at the Institut Pasteur in Lille as Part of the Phase IIa study on Totum-63, the Active Ingredient of Valedia® (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

ABB	50.98	2.82 %	K V
Logitech Intl	80.52	0.90 %	K V
CieFinRichemont	165.00	0.82 %	K V
Kuehne+Nagel Int	214.90	0.66 %	K V
Zurich Insur Gr	609.80	0.46 %	K V
Sika	230.40	-0.22 %	K V
Nestle	89.76	-0.82 %	K V
Roche Hldg G	306.00	-1.03 %	K V
Swisscom	522.00	-1.42 %	K V
UBS Group	29.06	-1.62 %	K V

Nachrichten zu Valbiotis SA

Aktien Top/Flop

Meistgelesene Nachrichten